180 related articles for article (PubMed ID: 15448116)
1. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.
Hirani VN; Raucy JL; Lasker JM
Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
3. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
6. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
7. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
8. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.).
Guo J; Nikolic D; Chadwick LR; Pauli GF; van Breemen RB
Drug Metab Dispos; 2006 Jul; 34(7):1152-9. PubMed ID: 16611861
[TBL] [Abstract][Full Text] [Related]
9. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.
Lillibridge JH; Liang BH; Kerr BM; Webber S; Quart B; Shetty BV; Lee CA
Drug Metab Dispos; 1998 Jul; 26(7):609-16. PubMed ID: 9660842
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.
Giraud C; Tran A; Rey E; Vincent J; Tréluyer JM; Pons G
Drug Metab Dispos; 2004 Nov; 32(11):1279-86. PubMed ID: 15483195
[TBL] [Abstract][Full Text] [Related]
13. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
14. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes.
Liu ZQ; Zhu B; Tan YF; Tan ZR; Wang LS; Huang SL; Shu Y; Zhou HH
J Pharmacol Exp Ther; 2002 Jan; 300(1):105-11. PubMed ID: 11752104
[TBL] [Abstract][Full Text] [Related]
15. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Khaliq Y; Gallicano K; Seguin I; Fyke K; Carignan G; Bulman D; Badley A; Cameron DW
Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
[TBL] [Abstract][Full Text] [Related]
16. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
17. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
[TBL] [Abstract][Full Text] [Related]
18. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
[TBL] [Abstract][Full Text] [Related]
19. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
Stresser DM; Kupfer D
Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]